Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines.

Girard N, Lhuissier E, Aury-Landas J, Cauvard O, Lente M, Boittin M, Baugé C, Boumédiene K.

J Bone Oncol. 2020 Feb 28;22:100283. doi: 10.1016/j.jbo.2020.100283. eCollection 2020 Jun.

2.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N.

J Thorac Oncol. 2020 Mar 9. pii: S1556-0864(20)30174-X. doi: 10.1016/j.jtho.2020.01.025. [Epub ahead of print]

PMID:
32165206
3.

Rapid detection of EGFR mutations in decalcified lung cancer bone metastasis.

Boureille A, Ferraro-Peyret C, Pontarollo G, Confavreux C, Pialat JB, Isaac S, Forest F, Yvorel V, Watkin E, Girard N, Brevet M.

J Bone Oncol. 2020 Jan 10;21:100277. doi: 10.1016/j.jbo.2020.100277. eCollection 2020 Apr.

4.

Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers.

Pontarollo G, Confavreux CB, Pialat JB, Isaac S, Forest F, Yvorel V, Maury JM, Girard N, Brevet M.

J Bone Oncol. 2020 Jan 8;21:100275. doi: 10.1016/j.jbo.2020.100275. eCollection 2020 Apr.

5.

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M.

J Thorac Oncol. 2020 Apr;15(4):499-519. doi: 10.1016/j.jtho.2019.12.107. Epub 2019 Dec 20. Review.

PMID:
31870882
6.

Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.

Roden AC, Fang W, Shen Y, Carter BW, White DB, Jenkins SM, Spears GM, Molina JR, Klang E, Segni MD, Ackman JB, Sanchez EZ, Girard N, Shumeri E, Revel MP, Chassagnon G, Rubinowitz A, Dicks D, Detterbeck F, Ko JP, Falkson CB, Sigurdson S, Segreto S, Del Vecchio S, Palmieri G, Ottaviano M, Marino M, Korst R, Marom EM.

J Thorac Oncol. 2020 Apr;15(4):568-579. doi: 10.1016/j.jtho.2019.12.108. Epub 2019 Dec 20.

PMID:
31870881
7.

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.

Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, Besse B, Molina TJ, Mazières J.

Biomark Res. 2019 Dec 4;7:28. doi: 10.1186/s40364-019-0177-8. eCollection 2019.

8.

The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors.

Ruffini E, Fang W, Guerrera F, Huang J, Okumura M, Kim DK, Girard N, Billè A, Boubia S, Cangir AK, Detterbeck F, Falkson C, Filosso PL, Giaccone G, Kondo K, Infante M, Lucchi M, Marino M, Marom EM, Nicholson AG, Rimner A, Rami-Porta R, Asamura H; Staging and Prognostic Factors Committee; Staging and Prognostic Factors-Thymic Domain Subcommittee; Staging and Prognostic Factors Subcommittees; Members of the Advisory Boards.

J Thorac Oncol. 2020 Mar;15(3):436-447. doi: 10.1016/j.jtho.2019.11.013. Epub 2019 Nov 27.

PMID:
31783179
9.

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.

Carausu M, Beddok A, Langer A, Girard N, Bidard FC, Massiani MA, Ricard D, Cabel L.

J Immunother Cancer. 2019 Nov 21;7(1):317. doi: 10.1186/s40425-019-0803-x.

10.

A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study.

Liu H, Gu Z, Qiu B, Detterbeck FC, Roden AC, Ruffini E, Okumura M, Girard N, Xiang Y, Liu Y, Du Z, Hao Y, Fu J, Zhang P, Pang L, Chen K, Wang Y, Yu Z, Mao T, Fang W; AME Thoracic Surgery Cooperative Group.

J Thorac Oncol. 2020 Mar;15(3):448-456. doi: 10.1016/j.jtho.2019.10.018. Epub 2019 Nov 11.

PMID:
31726106
11.

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

Levy A, Hendriks LEL, Berghmans T, Faivre-Finn C, GiajLevra M, GiajLevra N, Hasan B, Pochesci A, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Besse B, Novello S, Dingemans AC; EORTC Lung Cancer Group (EORTC LCG).

Eur J Cancer. 2019 Nov;122:109-114. doi: 10.1016/j.ejca.2019.09.012. Epub 2019 Oct 28.

PMID:
31671363
12.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG.

Clin Lung Cancer. 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007. Epub 2019 Oct 1.

PMID:
31648999
13.

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L.

EBioMedicine. 2019 Oct;48:191-202. doi: 10.1016/j.ebiom.2019.09.003. Epub 2019 Oct 21.

14.

Ligand-Controlled Regiodivergent Hydroformylation of Ynamides: A Stereospecific and Regioselective Access to 2- and 3-Aminoacroleins.

Wagner P, Donnard M, Girard N.

Org Lett. 2019 Nov 1;21(21):8861-8866. doi: 10.1021/acs.orglett.9b03566. Epub 2019 Oct 18.

PMID:
31625749
15.

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.

Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H, Kimmich M, Girard N, Tsai CM, Hsia TC, Brighenti M, Schumann C, Wang XA, Wijayawardana SR, Gruver AM, Wallin J, Mansouri K, Wacheck V, Chang GC.

J Thorac Oncol. 2020 Jan;15(1):80-90. doi: 10.1016/j.jtho.2019.10.003. Epub 2019 Oct 14.

PMID:
31622732
16.

The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.

Aury-Landas J, Girard N, Lhuissier E, Adouane D, Delépée R, Boumediene K, Baugé C.

Cell Physiol Biochem. 2019;53(4):731-745. doi: 10.33594/000000168.

17.

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E.

Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28.

PMID:
31600593
18.

Deep learning-based classification of mesothelioma improves prediction of patient outcome.

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, Girard N, Elemento O, Nicholson AG, Blay JY, Galateau-Sallé F, Wainrib G, Clozel T.

Nat Med. 2019 Oct;25(10):1519-1525. doi: 10.1038/s41591-019-0583-3. Epub 2019 Oct 7.

PMID:
31591589
19.

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.

Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Lang-Lazdunski L, Cree I, Rusch VW, Girard N, Galateau-Salle F.

J Thorac Oncol. 2020 Jan;15(1):29-49. doi: 10.1016/j.jtho.2019.08.2506. Epub 2019 Sep 20.

PMID:
31546041
20.

Versatile Synthetic Approach for Selective Diversification of Bicyclic Aza-Diketopiperazines.

Péron F, Riché S, Lesur B, Hibert M, Breton P, Fourquez JM, Girard N, Bonnet D.

ACS Omega. 2018 Nov 9;3(11):15182-15192. doi: 10.1021/acsomega.8b01752. eCollection 2018 Nov 30.

Supplemental Content

Loading ...
Support Center